Comparing the current results to its competitors, Sangamo Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -77.6 %, despite the revenue increase by the most of its competitors of 44.15 %, recorded in the same quarter.
Sangamo Therapeutics Inc 's Comment on Competition and Industry Peers
The company faces competition in gene therapy and genome engineering from biopharmaceutical companies, academic and research institutions, and government agencies. Competitors are developing technologies that rival the company's zinc finger (ZF) technology platform, including TALE proteins and the CRISPR-Cas editing system. Competitors may secure patent protection, obtain FDA approval, or commercialize products prior to the company. If the company initiates commercial sales, it may compete with firms possessing greater marketing, sales, distribution, and manufacturing capabilities. Additionally, any successful product candidate may compete with existing products that have established safety and efficacy profiles.
Eterna Therapeutics Inc is a biotechnology company that operates in the field of RNA therapeutics. Their business model focuses on developing innovative RNA-based therapies for various diseases by leveraging their proprietary platform technology. They aim to utilize their scientific expertise and strategic collaborations to advance the discovery, development, and commercialization of RNA therapeutics to improve patient outcomes.
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Maxcyte Inc's business model revolves around providing cell engineering and flow electroporation technology to facilitate drug discovery, development, and manufacturing processes.
Sources:
Sangamo Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sangamo Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
